Literature DB >> 35317531

Prevalence and interpretation of Xpert® Ultra trace results among presumptive TB patients.

L Chilukutu1, W Mwanza1, A D Kerkhoff2, P Somwe1, M Kagujje1, M Muyoyeta1.   

Abstract

BACKGROUND: The "trace call" results on Xpert® Ultra indicates extremely low TB levels and may be difficult to interpret. The prevalence of trace results among presumptive TB patients in high TB-HIV infection settings is unknown, as is the significance of divergent "trace call" result interpretations.
METHODS: Presumptive TB patients attending a public health facility in Lusaka, Zambia, were prospectively enrolled. Participants underwent several TB investigations, including sputum smear microscopy, Ultra testing, and culture. The diagnostic accuracy of Ultra (culture-based reference) and the number of patients recommended for TB treatment was assessed according to several different interpretation criteria for "trace call" results.
RESULTS: Among the 740 participants, 78 (10.5%) were Ultra-positive and an additional 37 (5.0%) had a "trace call" result. The prevalence of trace results did not differ according to HIV status (5.3% vs. 4.8%) or prior TB status (5.6% vs. 4.9%). Differing interpretations of trace results had modest effects on Ultra's sensitivity (range 79.3-82.6%) and specificity (range 94.3-99.2%), but increased the number of patients recommended for treatment by up to 44.9%.
CONCLUSIONS: Ultra trace results were common in this setting. The interpretation of trace results may substantially impact TB case yield.
© 2022 The Union.

Entities:  

Keywords:  CAD; HIV; diagnosis; tuberculosis

Year:  2022        PMID: 35317531      PMCID: PMC8908867          DOI: 10.5588/pha.21.0066

Source DB:  PubMed          Journal:  Public Health Action        ISSN: 2220-8372


  10 in total

1.  Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert MTB/RIF assay: a meta-analysis.

Authors:  Kai Chang; Weiping Lu; Junji Wang; Kejun Zhang; Shuangrong Jia; Fake Li; Shaoli Deng; Ming Chen
Journal:  J Infect       Date:  2012-02-27       Impact factor: 6.072

2.  Evaluation of Xpert MTB/RIF Ultra performance for pulmonary tuberculosis (TB) diagnosis in a city with high TB incidence in Brazil.

Authors:  Giovana Rodrigues Pereira; Márcia Silva Barbosa; Natan José Dutra Dias; Francine de Fraga Dos Santos; Karin Aline Rauber; Denise Rossato Silva
Journal:  Respir Med       Date:  2020-01-10       Impact factor: 3.415

3.  Xpert MTB/RIF Ultra and Xpert MTB/RIF for diagnosis of tuberculosis in an HIV-endemic setting with a high burden of previous tuberculosis: a two-cohort diagnostic accuracy study.

Authors:  Hridesh Mishra; Byron W P Reeve; Zaida Palmer; Judy Caldwell; Tania Dolby; Charissa C Naidoo; Jennifer G Jackson; Samuel G Schumacher; Claudia M Denkinger; Andreas H Diacon; Paul D van Helden; Florian M Marx; Robin M Warren; Grant Theron
Journal:  Lancet Respir Med       Date:  2020-02-14       Impact factor: 30.700

Review 4.  Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis.

Authors:  Jerry S Zifodya; Jonah S Kreniske; Ian Schiller; Mikashmi Kohli; Nandini Dendukuri; Samuel G Schumacher; Eleanor A Ochodo; Frederick Haraka; Alice A Zwerling; Madhukar Pai; Karen R Steingart; David J Horne
Journal:  Cochrane Database Syst Rev       Date:  2021-02-22

5.  Performance of Xpert MTB/RIF, Xpert Ultra, and Abbott RealTime MTB for Diagnosis of Pulmonary Tuberculosis in a High-HIV-Burden Setting.

Authors:  Wendy Stevens; Lesley Scott; Rebecca H Berhanu; Anura David; Pedro da Silva; Kate Shearer; Ian Sanne
Journal:  J Clin Microbiol       Date:  2018-11-27       Impact factor: 5.948

6.  Added Value of Xpert MTB/RIF Ultra for Diagnosis of Pulmonary Tuberculosis in a Low-Prevalence Setting.

Authors:  Onya Opota; Fathiah Zakham; Jesica Mazza-Stalder; Laurent Nicod; Gilbert Greub; Katia Jaton
Journal:  J Clin Microbiol       Date:  2019-01-30       Impact factor: 5.948

7.  Comparative evaluation of Xpert MTB/RIF and the new Xpert MTB/RIF ultra with respiratory and extra-pulmonary specimens for tuberculosis case detection in a low incidence setting.

Authors:  Claudio Piersimoni; Giancarlo Gherardi; Natascia Gracciotti; Antonella Pocognoli
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2019-03-12

8.  The New Xpert MTB/RIF Ultra: Improving Detection of Mycobacterium tuberculosis and Resistance to Rifampin in an Assay Suitable for Point-of-Care Testing.

Authors:  Soumitesh Chakravorty; Ann Marie Simmons; Mazhgan Rowneki; Heta Parmar; Yuan Cao; Jamie Ryan; Padmapriya P Banada; Srinidhi Deshpande; Shubhada Shenai; Alexander Gall; Jennifer Glass; Barry Krieswirth; Samuel G Schumacher; Pamela Nabeta; Nestani Tukvadze; Camilla Rodrigues; Alena Skrahina; Elisa Tagliani; Daniela M Cirillo; Amy Davidow; Claudia M Denkinger; David Persing; Robert Kwiatkowski; Martin Jones; David Alland
Journal:  mBio       Date:  2017-08-29       Impact factor: 7.867

9.  Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study.

Authors:  Susan E Dorman; Samuel G Schumacher; David Alland; Pamela Nabeta; Derek T Armstrong; Bonnie King; Sandra L Hall; Soumitesh Chakravorty; Daniela M Cirillo; Nestani Tukvadze; Nino Bablishvili; Wendy Stevens; Lesley Scott; Camilla Rodrigues; Mubin I Kazi; Moses Joloba; Lydia Nakiyingi; Mark P Nicol; Yonas Ghebrekristos; Irene Anyango; Wilfred Murithi; Reynaldo Dietze; Renata Lyrio Peres; Alena Skrahina; Vera Auchynka; Kamal Kishore Chopra; Mahmud Hanif; Xin Liu; Xing Yuan; Catharina C Boehme; Jerrold J Ellner; Claudia M Denkinger
Journal:  Lancet Infect Dis       Date:  2017-11-30       Impact factor: 25.071

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.